drugset / Trial / NCT06359509
Study of SYS6020 in BCMA-positive Multiple Myeloma
Phase 0
Not yet recruiting
10 enrolled
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
NaSingle-groupOpen-labelTreatment
Summary
This is a multi-center, phase I trial that studies the efficacy and recommended dose of BCMA CART cells in treating patients with BCMA-positive multiple myeloma (MM) that have not respond or relapsed after chemotherapy. B-cell maturation antigen (BCMA), a cell surface protein expressed on malignant plasma cell, has emerged as a very selective antigen to be targeted in novel immunotherapy for MM.
Timeline
- Start
- 2024-04
- Primary completion
- 2027-05
- Completion
- 2032-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | SYS6020 | Cell therapy | — | Intravenous |